Skip to main content

Drug Interactions between capmatinib and sulfinpyrazone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

sulfinpyrazone capmatinib

Applies to: sulfinpyrazone and capmatinib

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of capmatinib. According to the prescribing information, capmatinib is primarily metabolized by CYP450 3A4 and aldehyde oxidase. When administered with rifampin, a potent CYP450 3A4 inducer, capmatinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 56% and 67%, respectively. Coadministration with efavirenz, a moderate CYP450 3A4 inducer, decreased capmatinib Cmax and AUC by 34% and 44%, respectively. Data are not available for other, less potent inducers.

MANAGEMENT: The potential for diminished pharmacologic effects of capmatinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.

References

  1. (2020) "Product Information. Tabrecta (capmatinib)." Novartis Pharmaceuticals

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer